

Isobionics announces completion of Series C financing

24 March 2014



The natural ingredients company Isobionics B.V. announced today that it has completed a Series C financing round. The company received additional capital from DSM Venturing B.V., the corporate venture arm of Royal DSM (NYSE Euronext Amsterdam: DSM), the global Life Sciences and Materials Sciences company, and from Van Herk Ventures as well as from existing investors.

The investment will allow the company to expand the production capacity of its BioValencene™, BioNootkatone™ and Beta Elemene Pure™ products. "The investment by DSM Venturing, Van Herk Ventures and existing shareholders is a major milestone for Isobionics.

It allows us to further expand to larger commercial quantities and high-quality and cost competitive solutions for our customers. In parallel, the company can further develop new natural products for the Flavors & Fragrances and Agrochemical markets in the coming years. I am confident about the future of our company," said Toine Janssen, CEO and founder of Isobionics.

DSM Venturing led the Series C financing. Pieter Wolters, Managing Director of DSM Venturing commented: "We are pleased with the progress Isobionics has made and, in close consultation with the company and its prior investors, we have structured this financing round to fund Isobionics for success. We look forward to support the company in its next phase of growth and scale-up."

"We are very impressed by the current portfolio and future pipeline of Isobionics. We think Isobionics has the right management team to successfully execute the plans in this new phase of the company where commercialization becomes part of the business," says Dharminder Chahal, Investment manager of Van Herk Ventures.

Isobionics' shareholders are DSM Venturing, Van Herk Ventures, Brabant Life Sciences Seed Fonds, Innovatiefonds Provincie Limburg, I2S, Limburg Ventures, Industriebank LIOF, Technostars, Tailwind Business Solutions, and its personnel. The financial details of the investment were not disclosed.

About DSM – Bright Science. Brighter Living.™

Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders simultaneously. DSM

delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM's 24,500 employees deliver annual net sales of around €10 billion. The company is listed on NYSE Euronext. More information can be found at www.dsm.com.

About Van Herk Ventures

Van Herk Ventures is a part of the Rotterdam based Van Herk Groep. Van Herk Groep is founded by Aat van Herk (1951) and holds a portfolio of investments in real estate, energy and life sciences. Van Herk Ventures invests in the life sciences sector through direct investments in private and listed companies and in venture capital funds.